Analysis of [18F]FDOPA PET data (draft)
L-Dihydroxyphenylalanine (L-DOPA) is a precursor of catecholamines (dopamine, noradrenalin, and adrenalin). It crosses the blood-brain barrier (BBB) by facilitated diffusion, mainly by L-type amino-acid transporter (LAT1), and its conversion to dopamine is catalysed by aromatic amino acid decarboxylase (AADC). L-DOPA in the brain is mainly synthesized by hydroxylation of tyrosine. Dopamine is stored in the vesicles of the dopamine neurons. There are several L-DOPA analogues available for PET imaging, including 6-[18F]-L-DOPA (6-[18F]fluoro-l-3,4-dihydroxy-phenylalanine, [18F]FDOPA), 2-[18F]-L-DOPA (2-[18F]fluoro-l-3,4-dihydroxy-phenylalanine), [18F]FBPA (4-borono-2-18F-fluoro-l-phenylalanine), and [18F]FPDOPA (N-(2-[18F]fluoropropionyl)-3,4-dihydroxy-L-phenylalanine).
6-[18F]-L-DOPA (FDOPA) can be used to study the dopaminergic function in the brain, since its uptake reflects the activity of AAAD and subsequent build-up of labelled metabolites fluorodopamine (FDA), 6-[18F]fluorohomovanillic acid (FHVA), and 6-[18F]fluoro-3,4-dihydroxyphenylacetic acid (FDOPAC) (Barrio et al., 1997). FDOPA is also the most used PET tracer for studying hyperinsulinemia and neuroendocrine tumours (NETs).
[18F]FDOPA in tumour imaging
Tumour cell growth can be assessed using labelled amino acids, and [18F]FDOPA as an amino-acid analogue can be used for that purpose. Tumours generally have upregulated amino-acid transport, not only because of increased demand for protein synthesis, but also for usage as substrate for energy production. Incorporation of labelled amino-acid in other metabolic pathways than protein synthesis is not a drawback.
Transport of amino-acids into cells is not a rate-limiting step in peripheral tissues and tumours, but in the brain the uptake may be limited by the capacity of the carrier system or partial saturation by physiological amino-acids in plasma (Vaalburg et al., 1992).
Blocking of [18F]FDOPA metabolism may affect the tumour-to-background ratio, not necessarily for the better (Tuomela et al., 2013).
The other L-DOPA analogues than the 6-[18F]-L-DOPA have been mainly used for tumour imaging. 2-[18F]-L-DOPA has higher uptake in melanoma than 6-[18F]-L-DOPA (Ishiwata et al., 1989 and 1991). [18F]FBPA was developed for BNCT but has been used in diagnostics, too.
LAT1 is upregulated in the tumour tissue and endothelium, and the lower pH at the site of tumour also increases the LAT1 activity. Labelled amino-acid analogues are particularly useful for imaging brain tumours, because amino-acid uptake in the normal brain tissue is relatively low (Papin-Michault et al., 2016). [11C]methionine and [18F]fluoroethyl-L-tyrosine are commonly used tracers that also are transported by LAT1. Although correlation between LAT1 expression and SUV of amino-acid tracers has been seen in some studies, only minimal LAT1 expression is required for high [18F]FDOPA uptake in tumours. In addition, LAT4 may transport [18F]FDOPA. Different uptake mechanisms can occur among different tumours even within an individual (Feral et al., 2017). 3-O-methyl-FDOPA, one of the main metabolites of FDOPA, is also a substrate of LATs.
Peripheral metabolism of FDOPA leads to considerable concentrations of 18F-carrying metabolites in the plasma. The main metabolites in plasma are FDA, 3-O-sulphato-FDOPA, and 3-O-methyl-FDOPA (OMFD) (Firnau et al., 1988; Tuomela et al., 2013). Methylated metabolite can pass the blood-brain barrier (BBB). The rate of metabolism and relative proportions of plasma metabolites is affected by enzyme inhibitors (such as carbidopa) that are commonly administered before FDOPA PET study, or that are routinely used with L-DOPA medication (Tuomela et al., 2013).
Transport of FDOPA across BBB is affected by the competition with amino acids in the plasma and brain. DOPA is synthesized endogenously in the brain. Under normal physiological conditions the transport is close to saturation for both influx and efflux (Cunningham and Lammertsma, 1989).
[18F]FDOPA and its metabolites are excreted into urine, and accumulation is very high in the kidneys and urinary bladder (Ribeiro et al. 2005), which may be a problem in studying these organs, prostate, and the tail of the pancreas.
Analysis methods used in literature
Gjedde-Patlak graphical analysis with arterial plasma input
Reference region (cerebellum or occipital cortex) TAC is first subtracted from the ROI or image pixel TACs. Applied time range for line fit has been varied in the numerous studies applying the Patlak plot. Time range 20-70 min was used by Heinz et al (2005).
Because of the near saturation of FDOPA transport, K1 and k2 are approximately inversely proportional to the concentration of large neutral amino acids in the plasma and brain, respectively (Cunningham and Lammertsma, 1989). Leenders et al (1986) have shown that intravenous amino acid loading reduced FDOPA brain uptake about 3-fold compared to the fasting conditions.
Graphical analysis with reference tissue input
The slope of reference tissue MTGA (Patlak plot) is a function of k2 and k3:
The effect of competing amino acids in the brain is cancelled out from Kiref results.
Cerebellum and occipital cortex have been used as reference regions. For example, the rate of loss of nigrostriatal dopaminergic neurons in Parkinson's disease has been measured using Patlak plot with occipital cortex as reference region (Nurmi et al., 2001; Brück et al., 2009).
Standardized uptake value (SUV)
The semiquantitative SUV method is frequently used in oncological applications where absolute quantification is not necessary. Ribeiro et al. (2005) showed that the radioactivity concentration in pancreas, liver and lung remained rather constant (although small decrease can be observed) between 50 and 80 min after administration of [18F]FDOPA. This suggests that dynamic PET scanning is not necessary, but a static 5-min scan between 45 and 90 min should be informative enough (Becherer et al. 2004, Ribeiro et al. 2005). Although the concentration decrease with increasing time was small, it suggests that reversible uptake models (e.g. Logan graphical analysis) measuring distribution volume would be more appropriate for the analysis than irreversible uptake models (Gjedde-Patlak graphical analysis). If arterial plasma curve is not measured, a tissue-to-reference tissue (preferably tissues with high perfusion and blood content but low AADC activity) ratio approach may be related to distribution volume and be proven useful.
Tumour-to-normal tissue ratio (T/N) can be calculated from SUVs or directly from the regional radioactivity concentrations, and is also often used, especially in the brain, where the healthy hemisphere can be as the reference tissue.
- 4-Borono-2-18F-fluoro-l-phenylalanine [18F]FBPA
- Enzyme activity
- Protein synthesis
Barrio JR, Huang SC, Phelps ME. Biological imaging and the molecular basis of dopaminergic diseases. Biochem Pharmacol. 1997; 54: 341-348. doi: 10.1016/S0006-2952(97)00031-2.
Cumming P: Imaging Dopamine. Cambridge University Press, 2009. ISBN: 9780521790024. doi: 10.1017/CBO9780511575853.
Cunningham VJ, Lammertsma AA. Kinetic modelling of L-18F-fluorodopa uptake for PET studies in man. In: Positron Emission Tomography in Clinical Research and Clinical Diagnosis: Tracer Modelling and Radioreceptors, edited by C Beckers et al., 1989, 81-89. ISBN 978-0-7923-0254-4.
Firnau G, Garnett ES, Chirakal R, Sood S, Nahmias C, Schrobilgen G. [18F]Fluoro-L-dopa for the in vivo study of intracerebral dopamine. Int J Rad Appl Instrum A 1986; 37(8): 669-675. doi: 10.1016/0883-2889(86)90260-1.
Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem. 1987; 8(4): 1077-1082. doi: 10.1111/j.1471-4159.1987.tb05629.x.
Firnau G, Sood S, Chirakal R, Nahmias C, Garnett ES. Metabolites of 6-[18F]fluoro-L-dopa in human blood. J Nucl Med. 1988; 29(3): 363-369. PMID: 3126278.
Heinz A, Siessmeier T, Wrase J, Buchholz HG, Gründer G, Kumakura Y, Cumming P, Schreckenberger M, Smolka MN, Rösch F, Mann K, Bartenstein P. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 2005; 162(8): 1515-1520. doi: 10.1176/appi.ajp.162.8.1515.
Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, Smolka MN, Grunder G, Cumming P, Kumakura Y, Bartenstein P, Dolan RJ, Heinz A. Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci. 2008; 11(12): 1381-1382. doi: 10.1038/nn.2222.
Kumakura Y, Cumming P, Vernaleken I, Buchholz H-G, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Gründer G. Elevated [18F]Fluorodopamine turnover in brain of patients with Schizophrenia: an [18F]Fluorodopa positron emission tomography study. J Neurosci. 2007; 27(30): 8080-8087. doi: 10.1523/JNEUROSCI.0805-07.2007.
Kumakura Y, Danielsen EH, Gjedde A, Vernaleken I, Buchholz HG, Heinz A, Gründer G, Bartenstein P, Cumming P. Elevated [18F]FDOPA utilization in the periaqueductal gray and medial nucleus accumbens of patients with early Parkinson's disease. Neuroimage 2010; 49(4): 2933-2939. doi: 10.1016/j.neuroimage.2009.11.035.
Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RSJ. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol. 1986; 20: 258-262. doi: 10.1002/ana.410200212.
Misu Y, Goshima Y (eds.): Neurobiology of DOPA as a Neurotransmitter. CRC Press, 2006. ISBN: 978-0-415-33291-0.
Tuomela J, Forsback S, Haavisto L, Vahlberg T, Grönroos TJ, Solin O, Haaparanta-Solin M. Enzyme inhibition of dopamine metabolism alters 6-[18F]FDOPA uptake in orthotopic pancreatic adenocarcinoma. EJNMMI Res. 2013; 3: 18. doi: 10.1186/2191-219X-3-18.
Vaalburg W, Coenen HH, Crouzel C, Elsinga PH, Långström B, Lemaire C, Meyer GJ. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B. 1992; 19(2): 227-237. doi: 10.1016/0883-2897(92)90011-M.
Updated at: 2020-01-09
Created at: 2009-02-18
Written by: Vesa Oikonen